预测在857 MS患者的疾病活动IFNB-1b (PD5.009)

文摘

摘要目的:评估临床MRI /实验室参数获得和在第一年内IFNB-1b治疗前预测后续以前治疗天真名RRMS患者的疾病活动。

背景我们需要可靠的数据指导名RRMS患者的治疗决策。

设计/方法:分析857年名RRMS患者IFNB-1b(250微克,爆炸品处理,sc)至少1和2 - 3.5年以外的研究。潜在治疗前预测获得了年龄、性别、eds、疾病持续时间、数量的前2年复发,Gd +病变,T2病灶体积,T1黑洞病变体积。潜在的预测因子在治疗的第一年:复发,证实eds进展,累积大量的新MRI病灶,小伙子。评估疾病活动的结果在第一年复发年率(post-y1-ARR),折合成年率的新MRI病灶(post-y1-ARNL)。

结果:多变量模型被用来检查潜在的预测因子。基线预测post-y1-ARRs年龄(p= 0.011)和复发在前2年(p= 0.024)。年龄和基线T2病灶体积显著预测post-y1-ARNL (p< 0.0001,p= 0.011)。复发在第一年显著预测post-y1-ARR (p< 0.0001)。MRI病灶在年1显著预测post-y1-ARNL和ARR (p< 0.0001,p= 0.028)。小伙子在第一年显著预测post-y1-ARNL (p< 0.0001)但不是加勒比海盗。其他潜在因素没有显著预测疾病活动超出了第一年。

结论:年龄与IFNB-1b开始治疗前名RRMS患者和新MRI病灶在第一次治疗一年预测随后的临床和MRI疾病活动。复发在治疗第一年另外是有用的预测随后的复发率;T2病灶体积之前治疗和小伙子在第一年是有用的预测随后的核磁共振的活动。

支持:拜耳医疗制药有限公司

披露:哈尔顿博士与拜耳制药公司已经收到个人补偿活动,Idec, BioMS, Genzyme公司,默克公司Serono,诺华公司,赛诺菲-安万特和梯瓦扬声器和/或顾问。卡珀斯博士收到Acorda研究支持疗法,Actelion股价,Allozyne, BaroFold, Inc .)、拜耳制药公司,Bayhill疗法,Idec,勃林格殷格翰集团制药、公司,Elan公司公司,葛兰素史克,Inc . Glenmark制药公司,默克公司Serono, MediciNova,诺华公司,赛诺菲-安万特制药、Santhera制药、夏尔,罗氏诊断,神经科学Teva)联合制药公司,辉瑞公司,瑞士女士社会,瑞士国家研究基金会、欧盟,詹尼·Rubatto基金会,诺华和罗氏的研究基础。Goodin博士已经收到个人活动与默克公司Serono补偿,诺华,Berlex实验室、拜耳制药公司,Idec,先灵葆雅AG)和作为议长Teva神经科学,顾问和参与临床试验。Goodin博士已经收到了诺华的研究支持。奥康纳博士已经与阿伯特实验室收到个人补偿活动,公司,拜耳制药公司、Idec, BioMS, Cognosci,福岛第一制药公司Serono, Inc .,基因泰克,Inc .公司,诺华,罗氏诊断公司,赛诺菲-安万特制药、Inc . Teva神经科学、华平和惠氏制药公司担任顾问。奥康纳博士已经收到雅培实验室研究支持,拜耳制药公司、Idec, BioMS, Cognosci,福岛第一制药公司Serono, Inc .,基因泰克,Inc .公司,诺华,罗氏诊断公司,赛诺菲-安万特制药、Teva神经科学、华平和惠氏制药。菲利皮主持博士已经收到个人活动与ECTRIMS补偿,MSIF,爱尔兰,女士我们nms, Bayer-Schering, Biogen-Dompe AG)公司,默克公司Serono, Pepgen公司Teva,赛诺菲-安万特。菲利皮主持博士收到Teva,研究支持Bayer-Schering和公司。阿纳森博士已经收到个人补偿活动与拜耳先灵葆雅制药公司和Questcor公司担任顾问。阿纳森博士收到Questcor Pharmaceuticals Inc .研究支持Comi博士已经收到个人赔偿的活动与诺华,Teva神经科学,赛诺菲-安万特制药、公司,默克公司Serono,拜耳先灵葆雅,生原体Dompe。 Dr. Cook has received personal compensation for activities with Merck Serono, Bayer Healthcare, and EMD Serono. Dr. Cook has received personal compensation in an editorial capacity for Neurology Reviews. Dr. Jeffery has received personal compensation for activities with Berlex, Serono, Teva, Glaxo, and Pfizer. Dr. Petkau has received personal compensation for activities with The University of British Columbia, Bayer Schering, Biogen Idec, Merck-Serono, Opexa Therapeutics, Bayhill Therapeutics, Eisai Medical Research, Schering Plough and Solstice Neurosciences.Dr. Petkau has received research support from The Natural Sciences and Engineering Research Council of Canada and the Multiple Sclerosis Society of Canada. Dr. Bogumil has received personal compensation for activities with Bayer Pharmaceuticals, USA as an employee. Dr. Knappertz has received personal compensation for activities with Bayer Pharmaceuticals Corporation as an employee. Dr. Beckmann has received personal compensation for activities with Bayer Pharmaceuticals Corporation as an employee. Dr. Stemper has received personal compensation for activities with Bayer Schering Pharma AG, Germany as an employee. Dr. Pohl has received personal compensation for activities with Bayer Healthcare. Dr. Sandbrink has received personal compensation for activities with Bayer Schering Pharma AG as an employee. Dr. Sandbrink holds stock and/or stock options in Bayer Schering Pharma AG.